Life Biosciences, Inc., a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, announced the close of a fully-subscribed $80 million financing. The proceeds will support the company's operations into the second half of 2027, including the completion of its recently initiated Phase 1 clinical trial of ER-100 and the continued advancement of its broader Partial Epigenetic Reprogramming (PER) platform across multiple therapeutic indications.